Quantinuum Inc. (NASDAQ:QNT) just reported its first quarterly results as a public company, and Wall Street likes what it sees. The quantum computing firm beat revenue expectations, raised its outlook, and landed a marquee customer in Oracle. Analysts are calling it a "core quantum name to own."
Here's the rundown: Quantinuum posted an adjusted loss of 28 cents per share, slightly wider than the 26-cent loss analysts had penciled in. But revenue came in at $8 million, beating the $7.598 million estimate and jumping 279% from a year ago. The company also guided to full-year 2026 revenue of $28 million to $32 million, above the $26.485 million consensus. And it ended June with a hefty $2.1 billion in cash and short-term investments.
Both Rosenblatt Securities and TD Cowen came away impressed, maintaining their Buy ratings. Rosenblatt reiterated its $155 price target, while TD Cowen kept a Buy without a specific price forecast.
Rosenblatt: A 'Beat and Raise' With Growing Visibility
Rosenblatt described the quarter as a strong "beat and raise," noting revenue came in 5% above consensus. The firm also pointed out that the midpoint of Quantinuum's 2026 revenue outlook was 13% above the $26.5 million consensus estimate. Even better, the company provided an initial 2027 outlook calling for revenue growth of more than 100%, compared with Street expectations of about 68% growth.
Bookings are also picking up, which gives analysts more confidence in the numbers. Second-quarter bookings hit $4.3 million, nearly triple the first quarter's $1.3 million. Cumulative bookings reached about $81 million after the quarter, including the Oracle deal and other agreements. Management expects at least $120 million in bookings for 2026, up from $79 million in 2025.
Rosenblatt called Quantinuum a "core quantum name to own," citing its commercial backlog, the Oracle partnership, and progress on next-generation systems. The firm said its confidence in the company's technology roadmap and financial estimates increased after the quarter.
Oracle Deal: A Big Stamp of Approval
The headline news was Oracle Corporation's (NYSE:ORCL) decision to buy a Helios system for deployment in a U.S. Oracle Cloud Infrastructure data center. Rosenblatt noted that Oracle is a discerning technology customer, so its choice of Helios is strong validation for Quantinuum's technology.
The revenue impact won't be huge in 2026, Rosenblatt said, but it should become more meaningful around system delivery in 2027. The system will be tightly integrated with OCI's compute, networking, storage, identity, and data services. The two companies aim to support quantum, AI, and high-performance computing workflows in areas like pharmaceuticals, molecular discovery, materials science, and energy.
TD Cowen Sees GenAI Potential
TD Cowen also highlighted Quantinuum's stronger-than-expected outlook and improving visibility into 2027. The firm said the midpoint of the 2026 revenue forecast exceeded expectations and was backed by $81 million in cumulative bookings. That backlog and customer pipeline gave management enough confidence to forecast over 100% revenue growth in 2027.
The Oracle partnership is a major win, TD Cowen said, not just for its revenue potential but also for its role in quantum-enhanced generative AI computing. If successful, it could open new use cases, expand Quantinuum's software and algorithm expertise, and drive broader adoption of its quantum computing services.
TD Cowen also sees potential for additional on-premise system sales to hyperscalers, sovereign customers, research institutions, and enterprises. The firm noted that Quantinuum's latest Helios system offers about 50 high-fidelity logical qubits, which could expand its 2027 prospects even further.
Roadmap Progress
Analysts also pointed to steady progress on Quantinuum's technology roadmap. The Sol quantum processing unit remains on track for the second half of 2027, with early chips undergoing testing and validation. Apollo is still scheduled for 2029.
Quantinuum said it demonstrated near-five-nines logical fidelity on Helios, and Sol's trap chip has returned from fabrication and entered product validation. Apollo remains on schedule for 2029.
Rosenblatt said these developments are gradually reducing technology-roadmap risk and strengthening the path toward commercially relevant quantum computing. The firm maintained its $155 price target, which implies substantial upside from Quantinuum's $56.06 closing price on Aug. 11.
Price Action
Shares were up 21.94% at $68.36 at the time of publication on Wednesday, according to market data.
